ProSci Incorporated

Antibodies For All Your Research

Production and Services

c-Fos [pT232] glyc Antibody | catalog# XBP-4056

Background

c-Fos is a ~60 kDa immediate early gene product and a member of AP-1 family. c-Fos dimerizes with c-Jun to form the transcriptionally active complex AP-1, and functions in regulating cell proliferation and differentiation. c-Fos expression and activation are induced in many tumors (including breast cancer), and in response to a variety of stimuli (including growth factors, cytokines and stress). ERK1&2 mediate growth factor-induced c-Fos induction and transcripional activation by directly phosphorylating the carboxyl terminal domain of c-Fos. c-Fos is phosphorylated by Ras on threonine 232, the homologue of serine 73 of c-Jun, which results in augmenting its transcriptional activity.

Description
c-Fos [pT232] glyc Antibody
Lysates prepared from SKBR3 cells were resolved by SDS-PAGE on a 10% polyacrylamide gel and transferred to PVDF. Membranes were blocked with a 3% Milk-TBST buffer for one hour at room temperature, and incubated with c-Fos [pT232] antibody for two hours at room temperature in a 3% Milk-TBST buffer, following prior incubation with: no peptide (1), the non-phosphopeptide corresponding to the immunogen (2), a generic phosphothreonine-containing peptide (3), or, the phosphopeptide immunogen (4). After washing, membranes were incubated with goat F(ab')2 anti-rabbit IgG HRP conjugate and bands were detected using the Pierce SuperSignal™ method.

SIZE
PRICE(Select options)QTY
Credit Card Processing

Specifications

Formulation
Rabbit polyclonal immunoglobulin in Dulbecco's phosphate buffered saline (without Mg2+ and Ca2+), pH 7.3 (+/- 0.1), 50% glycerol, with 1.0 mg/mL BSA (IgG, protease free) as a carrier.
Clonality/Clone
This is a polyclonal antibody.
Specificity
Human c-Fos. Mouse and rat c-Fos (100% homologous) have not been tested, but are expected to react.
Source
c-Fos antibody was produced against a chemically synthesized phosphopeptide derived from the region of human c-Fos that contains threonine 232. The sequence is conserved in mouse and rat.
Purification
c-Fos antibody was purified from rabbit serum by sequential epitope-specific chromatography. The antibody has been negatively preadsorbed using a non-phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non-phosphorylated c-Fos. The final product is generated by affinity chromatography using a c-Fos-derived peptide that is phosphorylated at threonine 232.
Host
c-Fos [pT232] glyc antibody was raised in rabbit.

Please use anti-rabbit secondary antibodies.
Application
For Western blotting applications, we recommend using the antibody at a 1:1000 dilution.
Tested Application
WB
Buffer
Rabbit polyclonal immunoglobulin in Dulbecco's phosphate buffered saline (without Mg2+ and Ca2+), pH 7.3 (+/- 0.1), 50% glycerol, with 1.0 mg/mL BSA (IgG, protease free) as a carrier.
Storage
Store at -20˚C. We recommend a brief centrifugation before opening to settle vial contents. Then, apportion into working aliquots and store at -20˚C. For shipment or short-term storage (up to one week), 2 - 8˚C is sufficient.
Positive Control
  • SKBR3 cells treated with EGF.]
Species Reactivity
H
Reference
  1. Lu, Y., et al. (2004) Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells. Biochem. Biophys. Res. Commun. 313(3):709-715.
  2. Monje, P., et al. (2003) Phosphorylation of the carboxyl-terminal transactivation domain of c-Fos by extracellular signal-regulated kinase mediates the transcriptional activation of AP-1 and cellular transformation induced by platelet-derived growth factor. Mol. Cell. Biol. 23(19):7030-7043.
  3. Mikula, M., et al. (2003) The proto-oncoprotein c-Fos negatively regulates hepatocellular tumorigenesis. Oncogene 22(43):6725-6738.
  4. Wang, L.H., et al. (2003) The cis decoy against the estrogen response element suppresses breast cancer cells via target disrupting c-fos not mitogen-activated protein kinase activity. Cancer Res. 63(9):2046-2051.]